Literature DB >> 1835340

Susceptibility of Staphylococcus species and subspecies to teicoplanin.

T L Bannerman1, D L Wadiak, W E Kloos.   

Abstract

Twenty-four Staphylococcus species and their subspecies were examined for their susceptibilities to teicoplanin by disk diffusion (30-micrograms disk) and agar dilution for the determination of MICs. Moderately susceptible and resistant clinical strains were further tested for their susceptibilities to oxacillin and vancomycin. Teicoplanin resistance was not observed in the reference strains of the various Staphylococcus species isolated from healthy volunteers or animals. However, the novobiocin-resistant species Staphylococcus saprophyticus, Staphylococcus cohnii, Staphylococcus xylosus, Staphylococcus arlettae, Staphylococcus kloosii, and Staphylococcus gallinarum were less susceptible to teicoplanin (MIC, 2 to 8 micrograms/ml) than most of the novobiocin-susceptible species were (MIC, 0.5 to 4 micrograms/ml). Clinical isolates of coagulase-negative species were generally less susceptible to teicoplanin than were reference strains. Seven percent of the Staphylococcus epidermidis clinical strains were moderately susceptible (MIC, 16 micrograms/ml) to teicoplanin. Of these strains, 70% were oxacillin resistant. For Staphylococcus haemolyticus strains, 11% were resistant (MIC, greater than 16 micrograms/ml) and 21% were moderately susceptible to teicoplanin. Of these strains, 95% were oxacillin resistant, No strains of S. epidermidis or S. haemolyticus were intermediate or resistant to vancomycin. Teicoplanin appears to be less active in vitro against oxacillin-resistant S. haemolyticus. However, teicoplanin is an effective antimicrobial agent against many Staphylococcus species.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1835340      PMCID: PMC245293          DOI: 10.1128/AAC.35.9.1919

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  12 in total

1.  Simplified scheme for routine identification of human Staphylococcus species.

Authors:  W E Kloos; K H Schleifer
Journal:  J Clin Microbiol       Date:  1975-01       Impact factor: 5.948

2.  Teicoplanin, a new antibiotic from Actinoplanes teichomyceticus nov. sp.

Authors:  S Somma; L Gastaldo; A Corti
Journal:  Antimicrob Agents Chemother       Date:  1984-12       Impact factor: 5.191

Review 3.  Microbiological properties of teicoplanin.

Authors:  D Greenwood
Journal:  J Antimicrob Chemother       Date:  1988-01       Impact factor: 5.790

4.  Evaluation of teicoplanin and vancomycin disk susceptibility tests.

Authors:  A L Barry; C Thornsberry; R N Jones
Journal:  J Clin Microbiol       Date:  1986-01       Impact factor: 5.948

5.  Anti-staphylococcal activity of teicoplanin, vancomycin, and other antimicrobial agents: the significance of methicillin resistance.

Authors:  V E Del Bene; J F John; J A Twitty; J W Lewis
Journal:  J Infect Dis       Date:  1986-08       Impact factor: 5.226

6.  Teicoplanin-resistant coagulase-negative staphylococcus.

Authors:  A C Grant; R W Lacey; A M Brownjohn; J H Turney
Journal:  Lancet       Date:  1986-11-15       Impact factor: 79.321

7.  Comparative in vitro activities of teicoplanin, vancomycin, oxacillin, and other antimicrobial agents against bacteremic isolates of gram-positive cocci.

Authors:  E A Gorzynski; D Amsterdam; T R Beam; C Rotstein
Journal:  Antimicrob Agents Chemother       Date:  1989-11       Impact factor: 5.191

8.  Activities of daptomycin and teicoplanin against Staphylococcus haemolyticus and Staphylococcus epidermidis, including evaluation of susceptibility testing recommendations.

Authors:  D E Low; A McGeer; R Poon
Journal:  Antimicrob Agents Chemother       Date:  1989-04       Impact factor: 5.191

9.  Quality control limits for teicoplanin susceptibility tests and confirmation of disk diffusion interpretive criteria.

Authors:  A L Barry; R N Jones; T L Gavan; C Thornsberry
Journal:  J Clin Microbiol       Date:  1987-09       Impact factor: 5.948

10.  Identification of Staphylococcus species with the API STAPH-IDENT system.

Authors:  W E Kloos; J F Wolfshohl
Journal:  J Clin Microbiol       Date:  1982-09       Impact factor: 5.948

View more
  9 in total

Review 1.  Current perspectives on glycopeptide resistance.

Authors:  N Woodford; A P Johnson; D Morrison; D C Speller
Journal:  Clin Microbiol Rev       Date:  1995-10       Impact factor: 26.132

2.  Teicoplanin in cardiac surgery: intraoperative pharmacokinetics and concentrations in cardiac and mediastinal tissues.

Authors:  C Martin; P Bourget; M Alaya; A Sertin; C Atlani; K Ennabli; R Said
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

Review 3.  Antimicrobial susceptibility of coagulase-negative staphylococci.

Authors:  G L Archer; M W Climo
Journal:  Antimicrob Agents Chemother       Date:  1994-10       Impact factor: 5.191

4.  Molecular epidemiology of Staphylococcus epidermidis in a neonatal intensive care unit over a three-year period.

Authors:  P Villari; C Sarnataro; L Iacuzio
Journal:  J Clin Microbiol       Date:  2000-05       Impact factor: 5.948

5.  Emergence of teicoplanin-resistant coagulase-negative staphylococci.

Authors:  E Cercenado; M E García-Leoni; M D Díaz; C Sánchez-Carrillo; P Catalán; J C De Quirós; E Bouza
Journal:  J Clin Microbiol       Date:  1996-07       Impact factor: 5.948

6.  Prevalence of antibiotic resistance among clinical isolates of methicillin-resistant staphylococci.

Authors:  M F Tripodi; V Attanasio; L E Adinolfi; A Florio; P Cione; S Cuccurullo; R Utili; G Ruggiero
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-02       Impact factor: 3.267

Review 7.  Update on clinical significance of coagulase-negative staphylococci.

Authors:  W E Kloos; T L Bannerman
Journal:  Clin Microbiol Rev       Date:  1994-01       Impact factor: 26.132

Review 8.  Teicoplanin. A reappraisal of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  R N Brogden; D H Peters
Journal:  Drugs       Date:  1994-05       Impact factor: 9.546

9.  Comparative Genomics of Staphylococcus Reveals Determinants of Speciation and Diversification of Antimicrobial Defense.

Authors:  Rosanna Coates-Brown; Josephine C Moran; Pisut Pongchaikul; Alistair C Darby; Malcolm J Horsburgh
Journal:  Front Microbiol       Date:  2018-11-19       Impact factor: 5.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.